Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: A 17-week naturalistic study in Lithuania;Burnoje disperguojamojo mirtazapino veiksmingumas gydant depresiją, jo toleravimas ir pirmumo teikimas (septyniolikos savaičių natūralistinis tyrimas Lietuvoje)

Medicina

Volumn 45, Issue 10, 2009, Pages 778-784

  Danilevičiute, Vita ^a   Sveikata, Audrius ^b   Adomaitiene, Virginija ^b   Gumbrevičius, Gintautas ^b   Fokas, Vidmantas ^c   Sveikatiene, Renata ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^c Contract Research Organization Biomapas ^*  (Lithuania)

Author keywords

Depression; Efficacy; Mirtazapine orally disintegrating tablet; Naturalistic study; Tolerability

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROTHIXENE; DRUG DERIVATIVE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEPRESSION; FEMALE; HUMAN; INFORMATION PROCESSING; LITHUANIA; MALE; MENTAL HEALTH SERVICE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATION; ORAL DRUG ADMINISTRATION; PRIMARY HEALTH CARE; PSYCHOLOGICAL RATING SCALE; REMISSION; STATISTICAL ANALYSIS; TABLET; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROTHIXENE; CONTROLLED CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DEPRESSION; FEMALE; HUMANS; LITHUANIA; MALE; MENTAL HEALTH SERVICES; MIANSERIN; MIDDLE AGED; OBSERVATION; PRIMARY HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TABLETS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649098713     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina45100101     Document Type: Article

References (24)

1. Wittchen HU, Jacobi F. Size and burden of mental disorder in Europe: a critical review and appraisal of 27 studies. Eur J Neuropsychopharmacol 2005;15:357-76
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
3. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-105
4. The World Health Report 2001. Mental health: new understanding, new hope. Geneva: World Health Organization, 2001
5. Swenson JR. Quality of life in patients with coronary artery disease and the impact of depression. Curr Psychiatry Rep 2004;6(6):438-45
6. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54(3):227-40
7. Hahn CA, Dunn R, Halperin EC. Routine screening for depression in radiation oncology patients. Am J Clin Oncol 2004; 27(5):497-99
8. Kenedy SH, Lam RW, Nutt DJ, Thase ME. Treating depression effectively. London: Martin Dunitz, 2004. Medicina (Kaunas) 2009; 45(10)
9. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analysis of pooled data. Int Clin Psychopharmacol 1995; 10(Suppl):25-35
10. Roose SP, Nelson JC, Salzman C, Hollander SB, Rodrigues H. Open label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin 2003;19(8):737-46
11. Lavergne F, Berlin I, Gamma A, Stassen A, Angst J. Onset of improvement and response of to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. Neuropsych Dis Treat 2005;1(1):59-68
12. Delfini-Stula A, Bischof R. The results of the Swiss observational study of the new, fast-dissolving mirtazapine formulation in depressed patients. Int J Psych Clin Pract 2006;10(2):124-130
13. The ICD-10 classification of mental and behavioral disorders: clinical description and diagnostic guidelines. Geneva: World Health Organization; 1992
14. Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol 2005;20(2):87-91
15. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-20
16. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61; 656-63
17. Behnke K, Søgaard J, Martin S, Bäuml J, Ravindran AV, Agren H, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003;23(4):358-64
18. GuelfiJD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21(4):425-31
19. Benkert O, Szegedi A, Phillipp M, Kohnen R, Heinrich C, Heukels A, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double blind, randomized multicenter trial comparing the onset of action of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 2006;26(1):75-8
20. Danilevičiūtė V, Adomaitienė V, Sveikata A, Maičulaitis R, Kaduševičius E, Volbekas V. Gydytojo nurodymu{ogonek} laikymosi problema: pacientu{ogonek}, sergančiu{ogonek} depresija ir vartojančiu{ogonek} disper-guojama{ogonek}ja{ogonek} burnoje tablete{ogonek}, apklausos duomenys. (Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet.) Medicina (Kaunas) 2006;42(12): 1006-12
21. Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry 2003;64(Suppl 18):3-7
22. Keller MB. Remission versus response: the new gold stan-dard of antidepressant care. J Clin Psychiatry 2004;65 (Suppl 4):53-9
23. Burt VK. Plotting the course to remission: the search for better outcomes in the treatment of depression. J Clin Psychiatry 2004;65(Suppl 12):20-5
24. McIntyre RS, O'Donovan C. The human cost if not achieving full remission in depression. Can J Psychiatry 2004;49 (Suppl 3):10S-16S